HIGHLIGHTS
- who: Gianluca Mauri from the Innsbruck Medical University, Austria have published the article: Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer, in the Journal: (JOURNAL)
- what: The authors provide a molecular tumor board (MTB) discussion of two emblematic cases of uncommon MAP2K1 K57N mutated mCRC patients, commenting upon treatment decision making focused on anti-EGFR drug administration.
SUMMARY
After the identification of microsatellite stable (MSS), RAS and BRAF WT, MAP2K1 mutant mCRC, the authors retrospectively reviewed patients` records to evaluate . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.